- Molecular NameBisoprolol
- SynonymN/A
- Weight325.449
- Drugbank_IDDB00612
- ACS_NO66722-44-9
- Show 2D model
- LogP (experiment)1.87
- LogP (predicted, AB/LogP v2.0)2.4
- pka9.57
- LogD (pH=7, predicted)0.0
- Solubility (experiment)2.24 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)0.49
- LogSw (predicted, AB/LogsW2.0)6.87
- Sw (mg/ml) (predicted, ACD/Labs)7.1
- No.of HBond Donors2
- No.of HBond Acceptors5
- No.of Rotatable Bonds12
- TPSA59.95
- StatusFDA approved
- AdministrationN/A
- PharmacologyA drug belonging to the group of beta blockers, a class of drugs used primarily in cardiovascular diseases. More specifically, it is a selective type β1 adrenergic receptor blocker.
- Absorption_value96.0
- Absorption (description)Bisoprolol is almost completely absorbed after oral administration and undergoes only minimal first-pass metabolism.
- Caco_2N/A
- Bioavailability90.0
- Protein binding35.0
- Volume of distribution (VD)2.9 L/kg for healthy individuals; 3.1 L/kg for patients with impaired renal function; 3.9 L/kg for patients with acute hepatitis; 2.9 L/kg for those with liver cirrhosis
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmApproximately 50% of a dose is metabolised in the liver to pharmacologically inactive polar metabolites that are then excreted by the kidneys
- Half life10~12 h
- ExcretionThe remaining 50% is excreted unchanged by the kidneys. Less than 2% of a dose is excreted in faeces.
- Urinary ExcretionN/A
- Clerance14.2 L/h for healthy individuals; 7.8 L/h for patients with impaired renal function; 11.9 L/h for patients with acute hepatitis; 10.8 L/h for those with liver cirrhosis.
- ToxicityOral, mouse: LD50 = 100 mg/kg; Skin, rabbit: LD50 = 200 mg/kg; Skin, rat: LD50 = 500 mg/kg. Symptoms of overdose include congestive heart failure (marked by sudden weight gain, swelling of the legs, feet, and ankles, fatigue, and shortness of breath), difficult or labored breathing, low blood pressure, low blood sugar, and slow heartbeat.
- LD50 (rat)N/A
- LD50 (mouse)N/A